Exegenesis Bio Opens Philadelphia and Boston Offices and Announces Expansion Plans

PHILADELPHIA, PA, Sep 8, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the next phase of its business expansion, including plans to double in size during the next 12 months and opening of business offices in Philadelphia, research operations in Boston and a regional office in Singapore. Read full press release

Exegenesis Bio Completes Series B++ Financing; Raises $120 M to Date

PHILADELPHIA, PA, June 23, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the completion of its series B++ financing, raising over $50 M of venture investments in this round. The round was led by Hillhouse Capital Group and included existing investors LYFE Capital and BioTrack Capital, as well as new investors Temasek Holdings, CPE and Lake Bleu Capital. Read full press release

Scroll to top